The Montpelier-based company wants to revolutionize the treatment of tobacco, cannabis and alcohol addiction with herbal medicines. On June 16, it launched its listing on Euronext Growth, where it hopes to raise up to € 8 million. Should we try this bet?
Founded in 2006, the biotech specializing in botanical medicines wants to raise between 5.26 million and 8 million euros by listing on Euronext Growth.
The new shares will be issued between 3.40 euros to 4.60 euros each. Individuals can subscribe until June 29 and the first listing is scheduled for July 5.
NFL Biosciences is about to launch a phase II / III clinical study testing a drug based on tobacco leaf extracts to help smokers quit smoking.
An original approach
Two other products should enter the preclinical or clinical phase by the end of December, in addiction to cannabis and alcohol.
The fundraiser is expected to fund the company until the results of the smoking study in mid-2023. If successful, the product could be marketed, a priori via a partnership, from 2026. By then, NFL Biosciences wants to sign a licensing agreement in India in the coming months.
This stock market catalyst and the original medical approach encourage us to attempt this gamble, which is risky like all biotechs.
Subscribe. [ALNFL] Course objective: € 6.
Investment profile: speculative.
Next meeting: first listing, July 5.
